Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

A little over a year ago, the FDA approved Casgevy, a cellular therapy, for the treatment of sickle cell disease and beta-thalassemia. Vertex and CRISPR Therapeutics haven't started recording ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR, later this year, which will likely be a price catalyst and further support my long-term bullishness. FDA Approval Boosts Vertex Commercialization Plans Vertex Pharmaceuticals shares surged ...

Vertex and CRISPR Therapeutics haven't started recording ... the treatment process with over 50 patients. In December, the FDA approved Alyftrek, a new once-daily pill for patients with cystic ...